市場調査レポート

商品コード

1593480

加齢黄斑変性市場規模、シェア、成長分析、製品タイプ別、分子タイプ別、承認タイプ別、AMDタイプ別、エンドユーザー別、地域別 - 産業予測、2024年～2031年

Age-related Macular Degeneration Market Size, Share, Growth Analysis, By Product, By Molecule, By Approval Type, By Type of AMD By End User, By Region - Industry Forecast 2024-2031

出版日: 2024年11月09日
発行: SkyQuest
ページ情報: 英文 193 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

加齢黄斑変性（AMD）の世界市場規模は、2022年に92億米ドルと評価され、2023年の101億9,000万米ドルから2031年には231億6,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは10.80％で成長する見通しです。

加齢黄斑変性高齢者の視力低下の主な原因であるAMDは、主に網膜の中心部である黄斑部に影響を及ぼします。AMDには乾性AMDと湿性AMDがあり、その進行度や治療法は大きく異なります。乾性AMDはより一般的で、多くの場合、生活習慣の改善とビタミンの補給によって管理されます。一方、湿性AMDはまれではあるが、黄斑下の異常な血管増殖を直接標的とする抗VEGF注射など、より侵襲的な治療が必要となります。この治療法は、このような成長を引き起こすタンパク質を効果的に阻害するもので、AMDのタイプによって必要とされる医療介入が微妙に異なることを示しています。世界人口の高齢化に伴い、AMD治療市場は拡大しており、その主な要因は、高齢者におけるこの疾患の有病率の増加と薬物療法への依存度の高まりです。この動向は、より多くの人々が視力の維持を目指す中で、個人に合わせたヘルスケアソリューションの重要性を強調しています。その結果、AMD患者の急増と薬物介入の進歩は、AMD治療薬の堅調な市場推移を示唆しています。AMD管理のために生活習慣の改善や薬物療法を採用する高齢者の数が増加していることから、市場は持続的な成長を遂げる態勢にあり、ヘルスケアプロバイダーや製薬企業がこの人口層の進化するニーズに対応してAMD治療製品を革新・拡大する大きな機会があることを示しています。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- アラブ首長国連邦諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Biogen（US）
Formycon AG（Germany）
Coherus Biosciences（US）
Biocon（India）
Outlook Therapeutics, Inc.（US）
Teva Pharmaceutical Industries Ltd.（Israel）
Intas Pharmaceuticals Ltd.（India）
Chengdu Kanghong Pharmaceutical Group Co., Ltd.（China）
Ocular Therapeutix, Inc.（US）
Opthea Limited（Australia）
Kodiak Sciences Inc.（US）
Bio-Thera（China）
Amgen Inc.（US）
Alvotech（Iceland）
Stealth Biotherapeutics Inc.（US）
Alteogen Inc.（South Korea）
Ocumension Therapeutics（China）
Innovent（China）
Regeneron Pharmaceuticals, Inc.（US）
Shanghai Henlius Biotech, Inc.（China）

Product Code: SQMIG35I2357

Global Age-related Macular Degeneration Market size was valued at USD 9.2 billion in 2022 and is poised to grow from USD 10.19 billion in 2023 to USD 23.16 billion by 2031, growing at a CAGR of 10.80% during the forecast period (2024-2031).

Age-related macular degeneration (AMD), a leading cause of vision loss in the elderly, primarily affects the macula, the central area of the retina. The two prevalent forms of AMD-dry and wet-differ significantly in their progression and treatment approaches. Dry AMD is more common, often managed through lifestyle changes and vitamin supplementation, whereas wet AMD, though rarer, necessitates more invasive treatments, including anti-VEGF injections that directly target the abnormal blood vessel growth beneath the macula. This treatment method effectively inhibits the proteins responsible for such growth, illustrating the nuanced medical interventions required for different AMD types. As the global population ages, the market for AMD treatments is expanding, driven largely by the increasing prevalence of the disease among seniors and their growing reliance on medication. This trend underscores the importance of tailored healthcare solutions as more individuals seek to maintain their vision. Consequently, the surge in AMD cases, alongside advancements in pharmaceutical interventions, suggests a robust market trajectory for AMD therapies. With a rising number of seniors adopting lifestyle adjustments and medication for AMD management, the market is poised for sustained growth, indicating a significant opportunity for healthcare providers and pharmaceutical companies to innovate and expand their AMD treatment offerings in response to the evolving needs of this demographic.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Age-Related Macular Degeneration market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Age-Related Macular Degeneration Market Segmental Analysis

Global Age-related Macular Degeneration Market is segmented by Product, Molecule, Approval Type, Type of AMD, End User, and region. Based on Product, the market is segmented into Eylea & Eylea HD, Lucentis, Vabysmo, Syfovre, and Other Products. Based on Molecule, the market is segmented into Aflibercept, Faricimab, Ranibizumab, Pegcetacoplan, and Other Molecules. Based on Approval Type, the market is segmented into Biologics, and Biosimilars. Based on Type of AMD, the market is segmented into Wet AMD, and Dry AMD. Based on End User, the market is segmented into Hospitals, Long-Term Care Facilities, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Age-Related Macular Degeneration Market

The global age-related macular degeneration (AMD) market is significantly driven by the increasing elderly population, as this demographic is more vulnerable to the onset of AMD due to age-related physiological changes. As life expectancy continues to rise globally, the prevalence of AMD is expected to escalate, leading to a heightened demand for effective therapies and treatments aimed at managing and preventing vision loss. This surge in cases not only emphasizes the need for advanced medical solutions but also stimulates innovation and investment in research and development of AMD-targeted interventions, thereby propelling the overall market growth and addressing the impending vision health crisis among seniors.

Restraints in the Global Age-Related Macular Degeneration Market

One significant market restraint for the global age-related macular degeneration (AMD) market is the inadequate screening and diagnostic infrastructure in many regions. This deficiency not only leads to poor patient outcomes but also causes treatment delays, as individuals often remain unaware of their condition until it progresses to a more severe stage. The lack of awareness and information regarding available diagnostic tools further exacerbates this issue, limiting early interventions that are crucial for effective management of AMD. Consequently, the inefficiencies in current therapeutic options arise, stifling overall market growth and hindering advancements in patient care for AMD.

Market Trends of the Global Age-Related Macular Degeneration Market

The Global Age-Related Macular Degeneration (AMD) market is witnessing a significant trend towards the development and adoption of long-acting therapies, particularly extended-duration anti-VEGF treatments. This shift aims to address longstanding compliance issues associated with frequent injection schedules, as these innovative therapies reduce the treatment burden on patients by extending the duration between doses. By enhancing patient adherence and improving clinical outcomes, long-acting therapies are poised to drive market growth amidst previous challenges faced by conventional treatments. As a result, the AMD market is evolving with a focus on patient-centered solutions, indicating a promising future for therapeutic innovations in this domain.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Technology Analysis
Pricing Analysis
Value Chain Analysis
Supply Chain Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Case Study Analysis

Age-Related Macular Degeneration Drugs Market by Product

Market Overview
Eylea & Eylea HD
Lucentis
Vabysmo
Syfovre
Other Products

Age-Related Macular Degeneration Drugs Market by Molecule

Market Overview
Aflibercept
Faricimab
Ranibizumab
Pegcetacoplan
Other Molecules

Age-Related Macular Degeneration Drugs Market by Approval Type

Market Overview
Biologics
Biosimilars

Age-Related Macular Degeneration Drugs Market by Type of AMD

Market Overview
Wet AMD
Dry AMD

Age-Related Macular Degeneration Drugs Market by End User

Market Overview
Hospitals
Long-Term Care Facilities
Specialty Centers
Others

Age-Related Macular Degeneration Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Biogen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Formycon AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Coherus Biosciences (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Outlook Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intas Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chengdu Kanghong Pharmaceutical Group Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocular Therapeutix, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Opthea Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kodiak Sciences Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Thera (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alvotech (Iceland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stealth Biotherapeutics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alteogen Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocumension Therapeutics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Innovent (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai Henlius Biotech, Inc. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

加齢黄斑変性市場規模、シェア、成長分析、製品タイプ別、分子タイプ別、承認タイプ別、AMDタイプ別、エンドユーザー別、地域別 - 産業予測、2024年～2031年

Age-related Macular Degeneration Market Size, Share, Growth Analysis, By Product, By Molecule, By Approval Type, By Type of AMD By End User, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

加齢黄斑変性市場：製品タイプ別

加齢黄斑変性市場：分子タイプ別

加齢黄斑変性市場：承認タイプ別

加齢黄斑変性市場：AMDタイプ別

加齢黄斑変性市場：エンドユーザー別

加齢黄斑変性市場規模：地域別